Ganga Pharmaceuticals (539680) H2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
H2 25/26 earnings summary
22 May, 2026Executive summary
Audited financial results for the half year and full year ended March 31, 2026, were approved by the Board on May 21, 2026.
Statutory auditors issued an unmodified opinion on the financial statements.
Financial highlights
Revenue from operations for FY26 was ₹282.79 lakhs, up from ₹263.74 lakhs year-over-year.
Net profit for FY26 was ₹10.15 lakhs, compared to ₹7.90 lakhs in FY25.
Total income for FY26 was ₹310.70 lakhs, up from ₹307.33 lakhs in FY25.
Basic EPS for FY26 was ₹0.17, compared to ₹0.16 in FY25.
Outlook and guidance
Management confirmed the company continues as a going concern and there are no indications of cessation of operations.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ganga Pharmaceuticals
- H1 revenue was Rs 141.63 lakh; net profit was Rs 1.86 lakh.539680
H1 26/27 - Profit rose as revenue stayed nearly flat; IPO funding supported the core Ayurveda business.539680H2 15/16
- FY17 profit rose as Ayurveda product development and distribution remained central priorities.539680H2 16/17
- Revenue and profit improved as Ayurvedic product and distribution expansion remained central.539680H2 18/19
- FY18 profit rose as Ayurveda product and distribution plans advanced amid industry risks.539680H2 17/18
- Revenue declined, but profit edged up as COVID-19 disrupted FY20 operations.539680H2 19/20
- Pandemic disruption cut revenue and earnings as Ayurveda-focused growth plans advanced.539680H2 20/21
- Revenue and profit rose in FY22 despite macro headwinds; no dividend was recommended.539680H2 21/22
- FY23 income and profit edged higher as Ayurveda growth plans met industry and macro risks.539680H2 22/23